Delivery Order SPE2DB20D3303-SPE2DB25FA3QC
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $44,617.14 by the Defense Logistics Agency on September 11, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors. The contract is a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and represents a non-set-aside competitive award. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $29,794.79 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 8, 2025, with completion targeted for September 9, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. AmerisourceBergen,...
- The Defense Logistics Agency awarded a $17,619.85 delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injectors on July 23, 2025, with completion scheduled for July 24, 2025. This firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The work will be performed at AmerisourceBergen's corporate headquarters in...
- The Defense Logistics Agency (DLA) awarded a $38,968.29 delivery order to AmerisourceBergen Drug Corp on September 4, 2025, for the supply of Dupixent 300 mg/2 ml pen auto-injectors. This is a firm fixed price, non-set-aside delivery order with performance through September 5, 2025, and fulfillment from the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger indefinite delivery contract (IDC) with DLA Troop...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Dupixent 300 mg/2 ml pen injections (2 ml quantity) with a ceiling value of $21,486.82. This is a firm fixed price delivery order issued under a non-competitive, non-set-aside procurement. The order is set for ultimate completion by September 11, 2025, and will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency awarded a delivery order valued at $5,987.47 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pen injectors on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitive award, issued under firm fixed pricing, represents a child contract to AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The place of...
- The Defense Logistics Agency awarded a $83,783.16 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors, with an ultimate completion date of September 4, 2025. This competitively awarded contract, with no set-aside designation, will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The award represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $23,540.52 on August 18, 2025, for the supply of Dupixent 300 mg/2 mL pen injectors (2 mL units), with an ultimate completion date of August 19, 2025. This non-competitive, firm fixed-price delivery order will be fulfilled from the vendor's place of performance in Conshohocken, Pennsylvania. The award represents a child order issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a $29,308.15 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 12, 2025, for the supply of Dupixent 300 mg/2 ml pen injectors. The contract, which is a non-set-aside competitive award, carries an ultimate completion date of September 15, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader Indefinite...
- The Defense Logistics Agency awarded a $3,418.92 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Dupixent 200 mg/1.14 mL pen injectors. This is a firm fixed-price, non-set-aside contract with a completion date of August 20, 2025, and is being performed at the contractor's corporate headquarters in Conshohocken, Pennsylvania. The award represents a child delivery order under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA...
- SPE2DB20D3303Indefinite Delivery Contract
- SPE2DB20D3303-SPE2DB25FA3QCDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $3,418.92 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen auto-injectors on September 12, 2025, with a completion date of September 15, 2025. This competitive, non-set-aside contract represents a firm fixed-price delivery order for pharmaceutical supplies to be performed at the contractor's facility in Conshohocken, Pennsylvania. The award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999 and extending through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, has established itself as a critical federal medical procurement vendor through its extensive portfolio of delivery orders with the Defense Logistics Agency. The company's federal contracts demonstrate capability across diverse therapeutic domains, including specialty medications, vaccines, and medical devices, serving military and veteran healthcare systems. This specific delivery order for Dupixent, a biologic treatment for atopic dermatitis and other inflammatory conditions, reflects the company's role in supplying brand-name pharmaceutical products to support Department of Defense medical supply chain requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $3.4k | 9/12/25 |